EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study

Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Atsuki Fukushima, Koji Kawakita, Satoshi Kojima, Toka Nakamura, Hideki Suganami, K-232 Clinical Study Group

Graefe's Archive for Clinical and Experimental Ophthalmology · 2024

DOI: 10.1007/s00417-024-06388-y ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Hidenobu Tanihara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Biei Municipal Hospital, 3-8-35 Naka-machi, Biei Town, Kamikawa-gun, Hokkaido, 071-0207, Japan. tanihara@pearl.ocn.ne.jp. Hauptthemen laut MEDLINE: Intraocular Pressure, Ocular Hypertension, Sulfonamides, Isoquinolines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pressure (IOP)-lowering medication for glaucoma and ocular hypertension (OHT).

Methods

This prospective, multicentre (23 sites in Japan), open-label study enrolled patients with primary open-angle glaucoma (POAG), OHT or exfoliative glaucoma and assigned them to one of four combination therapy cohorts, based on previous treatment(s) received: prostaglandin (PG) analogue (Cohort 1); PG analogue and beta-adrenoceptor blocker (β-blocker) (Cohort 2); PG analogue, β-blocker and carbonic anhydrase inhibitor (Cohort 3); or other/no treatment (Cohort 4). After a ≥ 4-week screening period, eligible patients received twice-daily RBFC for 52 weeks in addition to the treatments they were already receiving. Efficacy was assessed by change in IOP from baseline through week 52. Adverse events and adverse drug reactions (ADRs) were monitored throughout.

Results

In total, 179 patients from Cohort 1 ( n = 48), Cohort 2 ( n = 44), Cohort 3 ( n = 41) and Cohort 4 ( n = 46) entered the RBFC treatment period. For all cohorts, mean IOP was significantly reduced at 11:00 (2 h after instillation of RBFC) through week 52 with the changes from baseline at week 52 of − 2.7 to − 4.1 mmHg across cohorts; all p < 0.001. Common ADRs were conjunctival hyperaemia (58%), allergic conjunctivitis (18%) and blepharitis (17%), most of which were mild in severity.

Conclusion

These data demonstrated the long-term efficacy and safety of RBFC, both alone and in combination with other anti-glaucoma agents. RBFC may offer a new treatment option for the long-term management of glaucoma and OHT.

Trial registration

Japan Registry of Clinical Trials Identifier: jRCT2080225063. Date of registration 17 February 2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intraocular PressureOcular HypertensionSulfonamidesIsoquinolinesBrimonidine TartrateAntihypertensive AgentsHumansMaleFemaleProspective StudiesAgedTreatment OutcomeMiddle AgedFollow-Up StudiesOphthalmic SolutionsTime FactorsDose-Response Relationship, DrugTonometry, OcularDrug CombinationsGlaucoma, Open-Angle

Stichwörter der Autor:innen

GlaucomaIntraocular pressureLong-term treatmentOcular hypertensionRipasudil-brimonidine fixed-dose combination

Substanzen

SulfonamidesK-115IsoquinolinesBrimonidine TartrateAntihypertensive AgentsOphthalmic SolutionsDrug Combinations

Autor:innen und Institutionen

  • Department of Ophthalmology, Biei Municipal Hospital, 3-8-35 Naka-machi, Biei Town, Kamikawa-gun, Hokkaido, 071-0207, Japan. tanihara@pearl.ocn.ne.jp.
  • Prof. Kazuo Iwata Memorial Kaijin Glaucoma Center, Kaiya Eye Clinic, Shizuoka, Japan.
  • Department of Ophthalmology, The University of Tokyo, Tokyo, Japan.
  • Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.
  • Department of Ophthalmology, Tsukazaki Hospital, Hyogo, Japan.
  • Pharmaceutical Clinical Development Management Department, Kowa Company, Ltd., Tokyo, Japan.

Förderung

  • Kowa Company

Zitieren

APA

Tanihara, H., Yamamoto, T., Aihara, M., Koizumi, N., Fukushima, A., Kawakita, K., Kojima, S., Nakamura, T., Suganami, H., & K-232 Clinical Study Group (2024). Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06388-y

Vancouver

Tanihara H, Yamamoto T, Aihara M, Koizumi N, Fukushima A, Kawakita K, et al. Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06388-y

BibTeX
@article{Tanihara2024,
  author = {Tanihara, Hidenobu and Yamamoto, Tetsuya and Aihara, Makoto and Koizumi, Noriko and Fukushima, Atsuki and Kawakita, Koji and Kojima, Satoshi and Nakamura, Toka and Suganami, Hideki and K-232 Clinical Study Group, K-232 Clinical Study Group},
  title = {Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2024},
  doi = {10.1007/s00417-024-06388-y}
}
Kostenlos starten →